Tirzepatide
FDA status: FDA has approved products that contain tirzepatide, including Mounjaro, Zepbound.
PubMed: 2,645 publications mention Tirzepatide, 354 of them trials or reviews. Search PubMed
- Tirzepatide for Obesity Treatment and Diabetes Prevention. Jastreboff AM et al. The New England journal of medicine, 2025. Randomized Controlled Trial, Clinical Trial, Phase III. PMID 39536238 · DOI
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Aronne LJ et al. The New England journal of medicine, 2025. Clinical Trial, Phase III. PMID 40353578 · DOI
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Dahl D et al. JAMA, 2022. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 35133415 · DOI
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Rosenstock J et al. Lancet (London, England), 2021. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 34186022 · DOI
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Look M et al. Diabetes, obesity & metabolism, 2025. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 39996356 · DOI
ClinicalTrials.gov: 303 registered studies. See all studies
- NCT07326111 A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese (Phase 4), recruiting
- NCT07293325 Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity, recruiting
MedlinePlus drug information ↗FDA label (DailyMed) ↗RxNorm 2601723 ↗PubChem CID 166567236 ↗Wikipedia ↗





